INCY Share Price Performance
US$102.06
30.34 (42.30%)
8.8% overvalued intrinsic discount
US$93.82
Fair Value
Price US$102.06
AnalystConsensusTarget US$93.82
AnalystLowTarget US$60.00
Fair ValueUS$93.82
Share Pricen/a
Incyte Corporation Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 87 Fair Values set on narratives written by author
INCY Community Narratives
AN
Fair Value US$93.82 8.8% overvalued intrinsic discount
Upcoming Clinical Data And New Management Will Shape Future Performance
0users have liked this narrative
0users have commented on this narrative
46users have followed this narrative
AN
Fair Value US$60 70.1% overvalued intrinsic discount
Future Revenues Will Decline As Regulatory And Competition Pressures Mount
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Upcoming Clinical Data And New Management Will Shape Future Performance
Key Takeaways Launches of new therapies and strong international uptake support diversified revenue growth and decreased geographic risk, especially in immunology and oncology markets. Focused investment in late-stage assets, precision medicine partnerships, and operating expense control enhance margin prospects and resilience against competitive pressures.Read more
0users have liked this narrative
0users have commented on this narrative
46users have followed this narrative
AN
US$93.82
8.8% overvalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
8.82% p.a.
Profit Margin
27.41%
Future PE
13.99x
Share price in 2028
US$114.45
Future Revenues Will Decline As Regulatory And Competition Pressures Mount
Key Takeaways Reliance on a single key product and slow diversification expose the company to major sales and profitability risks amid biosimilar competition and patent expiries. Increasing regulatory, pricing, and competitive pressures, along with diminishing R&D productivity, threaten both revenue growth and profit margins over the long term.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$60
70.1% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
5.52% p.a.
Profit Margin
20%
Future PE
13.76x
Share price in 2028
US$72.91
Recently Updated Narratives
AN
Upcoming Clinical Data And New Management Will Shape Future Performance
Fair Value: US$93.82 8.8% overvalued intrinsic discount
46 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Future Revenues Will Decline As Regulatory And Competition Pressures Mount
Fair Value: US$60 70.1% overvalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Incyte Corporation Key Details
About INCY
- Founded
- 1991
- Employees
- 2617
- CEO
- WebsiteView website
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
